Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.
Prescient Therapeutics Limited has received authorization from the European Clinical Trials Information System to commence a Phase 2a clinical trial of PTX-100 in Italy for patients with relapsed/refractory Cutaneous T-cell Lymphoma (CTCL). This milestone allows the company to activate trial sites and begin patient recruitment, marking a significant step towards providing a new treatment option for CTCL, a disease with high unmet medical needs.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized cancer treatments through advanced targeted and cellular therapies. The company is known for its innovative products such as PTX-100, a first-in-class compound targeting cancer growth pathways, and its cell therapy platforms like CellPryme-M and OmniCAR, which enhance the efficacy and adaptability of cancer treatments.
Average Trading Volume: 1,530,728
Technical Sentiment Signal: Buy
Current Market Cap: A$93.58M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.